Blocking endogenous IL-6 impairs mobilization of free fatty acids during rest and exercise in lean and obese men
© 2021 The Authors..
Lack of interleukin-6 (IL-6) leads to expansion of adipose tissue mass in rodents and humans. The exact underlying mechanisms have not been identified. In this placebo-controlled, non-randomized, participant-blinded crossover study, we use the IL-6 receptor antibody tocilizumab to investigate the role of endogenous IL-6 in regulating systemic energy metabolism at rest and during exercise and recovery in lean and obese men using tracer dilution methodology. Tocilizumab reduces fatty acid appearance in the circulation under all conditions in lean and obese individuals, whereas lipolysis (the rate of glycerol appearance into the circulation) is mostly unaffected. The fact that fatty acid oxidation is unaffected by IL-6 receptor blockade suggests increased re-esterification of fatty acids. Glucose kinetics are unaffected. We find that blocking endogenous IL-6 signaling with tocilizumab impairs fat mobilization, which may contribute to expansion of adipose tissue mass and, thus, affect the health of individuals undergoing anti-IL-6 therapy (Clinicaltrials.gov: NCT03967691).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
Cell reports. Medicine - 2(2021), 9 vom: 21. Sept., Seite 100396 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Trinh, Beckey [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.03.2022 Date Revised 03.03.2022 published: Electronic-eCollection ClinicalTrials.gov: NCT03967691 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.xcrm.2021.100396 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331632306 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331632306 | ||
| 003 | DE-627 | ||
| 005 | 20231225213903.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xcrm.2021.100396 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1105.xml |
| 035 | |a (DE-627)NLM331632306 | ||
| 035 | |a (NLM)34622233 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Trinh, Beckey |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Blocking endogenous IL-6 impairs mobilization of free fatty acids during rest and exercise in lean and obese men |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.03.2022 | ||
| 500 | |a Date Revised 03.03.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a ClinicalTrials.gov: NCT03967691 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. | ||
| 520 | |a Lack of interleukin-6 (IL-6) leads to expansion of adipose tissue mass in rodents and humans. The exact underlying mechanisms have not been identified. In this placebo-controlled, non-randomized, participant-blinded crossover study, we use the IL-6 receptor antibody tocilizumab to investigate the role of endogenous IL-6 in regulating systemic energy metabolism at rest and during exercise and recovery in lean and obese men using tracer dilution methodology. Tocilizumab reduces fatty acid appearance in the circulation under all conditions in lean and obese individuals, whereas lipolysis (the rate of glycerol appearance into the circulation) is mostly unaffected. The fact that fatty acid oxidation is unaffected by IL-6 receptor blockade suggests increased re-esterification of fatty acids. Glucose kinetics are unaffected. We find that blocking endogenous IL-6 signaling with tocilizumab impairs fat mobilization, which may contribute to expansion of adipose tissue mass and, thus, affect the health of individuals undergoing anti-IL-6 therapy (Clinicaltrials.gov: NCT03967691) | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a IL-6 receptor | |
| 650 | 4 | |a Interleukin-6 | |
| 650 | 4 | |a exercise | |
| 650 | 4 | |a fatty acids | |
| 650 | 4 | |a glycerol | |
| 650 | 4 | |a lipolysis | |
| 650 | 4 | |a metabolism | |
| 650 | 4 | |a obesity | |
| 650 | 4 | |a stable isotopes | |
| 650 | 4 | |a tocilizumab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Carbohydrates |2 NLM | |
| 650 | 7 | |a Fatty Acids |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Receptors, Interleukin-6 |2 NLM | |
| 650 | 7 | |a Glucagon |2 NLM | |
| 650 | 7 | |a 9007-92-5 |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 650 | 7 | |a Hydrocortisone |2 NLM | |
| 650 | 7 | |a WI4X0X7BPJ |2 NLM | |
| 700 | 1 | |a Peletier, Merel |e verfasserin |4 aut | |
| 700 | 1 | |a Simonsen, Casper |e verfasserin |4 aut | |
| 700 | 1 | |a Plomgaard, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Karstoft, Kristian |e verfasserin |4 aut | |
| 700 | 1 | |a Klarlund Pedersen, Bente |e verfasserin |4 aut | |
| 700 | 1 | |a van Hall, Gerrit |e verfasserin |4 aut | |
| 700 | 1 | |a Ellingsgaard, Helga |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports. Medicine |d 2020 |g 2(2021), 9 vom: 21. Sept., Seite 100396 |w (DE-627)NLM310587662 |x 2666-3791 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2021 |g number:9 |g day:21 |g month:09 |g pages:100396 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xcrm.2021.100396 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2021 |e 9 |b 21 |c 09 |h 100396 | ||